Physician

Asad Dean, MD

According to 2025 Medicare claims, Asad Dean, MD (NPI: 1760441885) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1033386578; TIN: 752131429) and primary practice location at 76104-2154. Dean is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Dean's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 581 traditional Medicare patients, billed 74,944 HCPCS/CPT codes, and received $1,609,951 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,281 prescription claims across 248 beneficiaries totaling $3,338,137 in drug costs, led by Imbruvica (Ibrutinib). 2021 DME data shows 204 claims. Open Payments data shows 183 records totaling $114,896. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,654,915 and ending at $3,338,137. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	446	87,664	$1,490,245
2016	504	91,386	$1,530,323
2017	635	69,528	$1,359,109
2018	604	81,331	$1,434,348
2019	594	85,217	$1,632,369
2020	554	63,412	$1,446,322
2021	526	64,466	$1,400,760
2022	443	38,934	$894,469
2023	535	82,421	$1,618,988
2024	581	74,944	$1,609,951

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	199	1,412	$1,654,915
2016	185	1,266	$1,701,057
2017	205	1,486	$2,238,667
2018	234	1,501	$2,649,306
2019	199	1,402	$2,296,260
2020	182	1,510	$2,150,928
2021	185	1,191	$1,697,016
2022	203	1,187	$2,484,312
2023	196	1,121	$1,835,269
2024	248	1,281	$3,338,137

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	67	$27,608
2016	N/R	N/R	N/R
2017	N/R	150	$67,651
2018	N/R	226	$99,069
2019	N/R	218	$98,875
2020	N/R	204	$100,865
2021	N/R	204	$103,751
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	111	193	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	281	651	$91
80053	Blood test, comprehensive group of blood chemicals	313	742	$10
36415	Insertion of needle into vein for collection of blood sample	303	792	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	295	742	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	57	1,616	$874,192
Revlimid	Lenalidomide	33	882	$619,775
Brukinsa	Zanubrutinib	30	900	$349,700
Pomalyst	Pomalidomide	14	392	$313,533
Ibrance	Palbociclib	13	364	$194,455

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	180	$112,028	Lilly USA, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$2,868	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Asad Dean, MD?

Tedicare shows public-source Medicare data for Asad Dean, MD (NPI 1760441885), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Asad Dean, MD have ACO affiliation data?

Asad Dean, MD is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Asad Dean, MD?

Asad Dean, MD is linked to TEXAS ONCOLOGY PA (billing NPI 1033386578) in the available physician profile data.

Does Asad Dean, MD have Open Payments data?

Asad Dean, MD has 183 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.